A specific theme concerning KHK6640, an anti-amyloid-beta peptide antibody, including the Phase I clinical trials in Europe and Japan conducted by Kyowa Hakko Kirin and the integration of its R&D and sales structure following the absorption merger with イムナス・ファーマ.